Breast Cancer | Specialty

Chemo Alone May Be Optimal in HER2-Positive Patients With High TIL Levels

December 10th 2014

Among HER2-positive breast cancer patients treated with chemotherapy alone, women with high levels of stromal tumor-infiltrating lymphocytes had an 80% lower likelihood of disease recurrence compared to those with lower TIL counts.

Analyzing CTCs Using Next-Generation Sequencing

December 5th 2014

Next-Generation of CTC Technology

December 5th 2014

Clinical Utility of Circulating Tumor Cells

December 5th 2014

Latest News & Insight: December 5, 2014

December 5th 2014

Joan Lunden to Keynote 32nd Annual Miami Breast Cancer Conference

December 5th 2014

Physicians' Education Resource®, LLC (PER®), to Sponsor Innovative CME Conference for Breast Cancer Specialists

Dr. Carey Discusses Treatment Challenges in TNBC

December 4th 2014

Lisa A. Carey, MD, the Division Chief of Hematology and Oncology at the University of North Carolina and the Physician-in-Chief at North Carolina Cancer Hospital, discusses triple-negative breast cancer (TNBC) and the importance of understanding how it differs from other types of breast cancer.

From Bedside to Bench

November 29th 2014

Based on a current laboratory research project, Zarah Dulce F. Lucas, MD, discusses microRNAs and their potential to predict brain metastases in patients with triple-negative and HER2-positive breast cancer.

PARP Inhibitors for Breast and Ovarian Cancers

November 26th 2014

PARP inhibitors represent an exciting new class of anticancer agents and are currently being evaluating in phase III for a number of different indications.

Pre-Chemo Abiraterone Extends Survival in CRPC

November 21st 2014

ADT With GnRH Antagonists in Prostate Cancer

November 21st 2014

Upcoming Advances for GU Cancers

November 21st 2014

Latest News & Insight: November 20, 2014

November 21st 2014

Updated Data Continues to Support Adjuvant Trastuzumab

November 20th 2014

Adding 1-year of adjuvant trastuzumab to chemotherapy continues to demonstrate an improvement in overall survival (OS) and disease-free survival (DFS) for patients with early-stage HER2-positive breast cancer

Frontline T-DM1 on Horizon in Metastatic Breast Cancer

November 20th 2014

Treatment with the antibody-drug conjugate T-DM1 (ado-trastuzumab emtansine; Kadcyla) has demonstrated promising clinical efficacy with lower toxicity across a variety of settings for patients with HER2-positive metastatic breast cancer when compared with standard therapies.

Fewer CNS Metastases, Similar Efficacy Seen With Neratinib Versus Trastuzumab

November 14th 2014

Frontline treatment with neratinib in combination with paclitaxel demonstrated similar ORR and PFS as the combination of trastuzumab and paclitaxel while lowering the incidence of CNS metastases in patients with locally recurrent or metastatic HER2-positive breast cancer.

Novel Radiotherapy Techniques Expand Options for Breast Cancer Patients

November 12th 2014

Those of us who have treated patients with breast cancer for any extended period of time can likely share anecdotes about watching the treatment of this disease evolve to levels many of us could only have imagined when we began practicing.

Development of PI3K Inhibitors in Breast Cancer

November 7th 2014

The PI3K pathway is the most frequently altered pathway in cancer, and its activation has been shown to confer resistance to endocrine and HER2-targeted therapies preclinically.

Expert Critiques Adjuvant Tamoxifen Guideline for HR-Positive Breast Cancer

November 6th 2014

In May 2014, ASCO issued guidelines recommending the administration of adjuvant tamoxifen for 10 years in women with stage I-III hormone receptor (HR)-positive breast cancer, based on data from the collection of 5 clinical trials.

Eribulin Improves Survival in Metastatic Triple-Negative Breast Cancer

November 3rd 2014

Treatment with eribulin mesylate improved overall survival of patients with triple-negative and HER2-negative metastatic breast cancer compared with standard chemotherapies.